業績

• 2023年
• 2022年
• 2021年
• 2020年
• 2019年
• 2018年
• 2017年
• 2016年
• 2015年
• 2014年
• 2013年
• 2012年
• 2011年
• 2010年
• 2009年
• 2008年
• 2007年
• 2006年

2016年

• 原著
• 症例報告
• 総説
• その他

原著

• Tatsumoto N, Arioka M, Yamada S, Takahashi-Yanaga F, Tokumoto M, Tsuruya K, Kitazono T, Sasaguri T.

  Inhibition of GSK-3β increases trabecular bone volume but not cortical bone volume in adenine-induced uremic mice with severe hyperparathyroidism.
  

  Physiol Rep. 2016 Nov;4(21). pii: e13010.

• Sakoh T, Nakayama M, Tsuchihashi T, Yoshitomi R, Tanaka S, Katafuchi E, Fukui A, Shikuwa Y, Kitazono T, Tsuruya K.

  Associations of fibroblast growth factor 23 with urate metabolism in patients with chronic kidney disease.

  Metabolism 65 (10): 1498-1507, 2016

• Torisu K, Zhang X, Nonaka M, Kaji T, Tsuchimoto D, Kajitani K, Sakumi K, Torisu T, Cjida K, Sueishi K, Kubo M, Hata J, Kitazono T, Kiyohara Y, Nakabeppu Y.

  PKCη deficiency improves lipid metabolism and atherosclerosis in apolipoprotein E-deficient mice.

  Genes to Cells 21 (10): 1030-1048, 2016

• Torisu K, Singh KK, Torisu T, Lovren F, Liu J, Pan Y, Quan A, Ramadan A, Al-Omran M, Pankova N, Boyd SR, Verma S, Finkel T.

  Intact endothelial autophagy is required to maintain vascular lipid homeostasis.

  Aging Cell 15 (1): 187-191, 2016

• Masutani K, Tsuchimoto A, Yamada T, Hirakawa M, Mitsuiki K, Katafuchi R, Hirakata H, Kitazono T, Tsuruya K; West Japan Study Group for Therapy of IgA Nephropathy Investigators.

  Comparison of steroid-pulse therapy and combined with mizoribine in IgA nephropathy: a randomized controlled trial.

  Clin Exp Nephrol 20: 896-903, 2016

• Takae K, Nagata M, Hata J, Mukai N, Hirakawa Y, Yoshida D, Kishimoto H, Tsuruya K, Kitazono T, Kiyohara Y, Ninomiya T.

  Serum uric acid as a risk factor for chronic kidney disease in a Japanese community - The Hisayama Study.

  Circ J 80 (8): 1857-1862, 2016

• Tsuruya K, Yoshida H, Suehiro T, Fujisaki K, Masutani K, Kitazono T.

  Erythropoiesis-stimulating agent slows the progression of chronic kidney disease: a possibility of a direct action of erythropoietin.

  Ren Fail 38 (3): 390-396, 2016

• Yoshitomi R, Nakayama M, Sakoh T, Fukui A, Shikuwa Y, Tominaga M, Tsuchihashi T, Tsuruya K, Kitazono T.

  Plasma B-type natriuretic peptide concentration is independently associated with kidney function decline in Japanese patients with chronic kidney disease.

  J Hypertens 34 (4): 753-761, 2016

• Tanaka S, Ninomiya T, Taniguchi M, Fujisaki K, Tokumoto M, Hirakata H, Ooboshi H, Kitazono T, Tsuruya K.

  Comparison of oral versus intravenous vitamin D receptor activator in reducing infection-related mortality in hemodialysis patients: the Q-Cohort Study.

  Nephrol Dial Transplant 31 (7): 1152-1160, 2016

• Tanaka S, Ninomiya T, Katafuchi R, Masutani K, Nagata M, Tsuchimoto A, Hirakata H, Kitazono T, Tsuruya K.

  The effect of renin-angiotensin system blockade on the incidence of end-stage renal disease in IgA nephropathy.

  Clin Exp Nephrol 20 (5): 689-698, 2016

• Yamada S, Tsuruya K, Taniguchi M, Tokumoto M, Fujisaki K, Hirakata H, Fujimi S, Kitazono T.

  Association between serum phosphate levels and stroke risk in patients undergoing hemodialysis: The Q-Cohort Study.
  

  Stroke 47 (9): 2189-2196, 2016

• Yamada S, Tsuruya K, Yoshida H, Tokumoto M, Ueki K, Ooboshi H, Kitazono T.

  Factors associated with the serum myostatin level in patients undergoing peritoneal dialysis: potential effects of skeletal muscle mass and vitamin D receptor activator use.

  Calcif Tissue Int 99 (1): 13-22, 2016

• Yamada S, Tokumoto M, Tatsumoto N, Tsuruya K, Kitazono T, Ooboshi H.

  Very low protein diet enhances inflammation, malnutrition, and vascular calcification in uremic rats.
  

  Life Sci 146:117-123, 2016

• Yamada S, Ueki K, Tokumoto M, Suehiro T, Kimura H, Taniguchi M, Fujimi S, Kitazono T, Tsuruya K.

  Effects of Lowering Dialysate Calcium Concentration on Mineral and Bone Disorders in Chronic Hemodialysis Patients: Conversion from 3.0 mEq/L to 2.75 mEq/L.

  Ther Apher Dial 20 (1): 31-39, 2016

• Eriguchi M, Tsuruya K, Yoshida H, Haruyama N, Tanaka S, Tsuchimoto A, Fujisaki K, Torisu K, Masutani K, Kitazono T.

  Extended swan-neck catheter with upper abdominal exit-site reduces peritoneal dialysis-related infections.

  Ther Apher Dial 20 (2): 158-164, 2016

• Eriguchi M, Yotsueda R, Torisu K, Kawai Y, Hasegawa S, Tanaka S, Noguchi H, Masutani K, Kitazono T, Tsuruya K.

  Assessment of urinary angiotensinogen as a marker of podocyte injury in proteinuric nephropathies.

  Am J Physiol Renal Physiol 310 (4): F322-F333, 2016

• Washio M, Higashi H, Sugawara K, Tsusumi C, Sakita M, Ide Y, Tsuruya K, Kitazono T, Kondo K, Ide S.

  Influenza vaccination and other factors related to the development of influenza-like illness among patients on chronic hemodialysis in a Japanese dialysis facility.

  Ther Apher Dial 20 (2): 122-126, 2016

• Hasegawa K, Tsukamoto K, Kunimi M, Asahi K, Iseki K, Moriyama T, Yamagata K, Tsuruya K, Fujimoto S, Narita I, Konta T, Kondo M, Kimura K, Ohashi Y, Watanabe T.

  Control status of atherosclerotic cardiovascular risk factors among Japanese high-risk subjects.

  J Atheroscler Thromb 23 (8): 991-1003, 2016

• Nagasawa Y, Yamamoto R, Shinzawa M, Hasuike Y, Kuragano T, Isaka Y, Nakanishi T, Iseki K, Yamagata K, Tsuruya K, Yoshida H, Fujimoto S, Asahi K, Moriyama T, Watanabe T.

  Body mass index modifies an association between self-reported regular exercise and proteinuria.

  J Atheroscler Thromb 23 (4): 402-412, 2016

症例報告

• Yamada S, Ueki K, Kawai Y, Sako T, Shimomura Y, Tsuchimoto A, Tanaka S, Matsui R, Maeda H, Tokumoto M, Ooboshi H, Kitazono T, Tsuruya K.

  Extrapulmonary tuberculosis presented as fever of unknown origin in two patients with endstage kidney disease not on dialysis: usefulness of 18-FDG-PET/CT in the diagnostic localization of fever of unknown origin.

  CEN Case Rep 5 (1), 11-17, 2016

• Aihara S, Yamada S, Uchida Y, Arase H, Tsuchimoto A, Nakano T, Taniguchi M, Higashi H, Kitazono T, Tsuruya K

  Calciphylaxis treated with sodium thiosulfate and hyperbaric oxygen in a non-dialyzed patient with chronic kidney disease.
  

  Intern Med 55 (14): 1899-1905, 2016

• Hiyamuta H, Yamada S, Matsukuma Y, Tsuchimoto A, Nakano T, Taniguchi M, Masutani K, Yoshimoto G, Muta T, Akashi K, Kitazono T, Tsuruya K.

  Light chain deposition disease in an older adult patient successfully treated with long-term administration of bortezomib, melphalan and prednisone.

  Intern Med 55 (10): 1319-1325, 2016

• Yamasaki K, Haruyama N, Taniguchi M, Nishida T, Tominaga R, Kitazono T, Tsuruya K.

  Subacute pulmonary embolism in a hemodialysis patient, successfully treated with surgical thrombectomy.

  CEN Case Rep 5 (1): 74-77, 2016

• Hara M, Yamada S, Nakamura Y, Oka H, Kamimura T, Nakane S, Tsuruya K, Harada A.

  Autoimmune autonomic ganglionopathy manifesting as acute-onset orthostatic hypotension in a patient undergoing peritoneal dialysis: a case report.

  CEN Case Rep 5 (1): 5-10, 2016

総説

• Nakano T, Fukuda D, Koga J, Aikawa M.

  Delta-Like Ligand 4-Notch Signaling in Macrophage Activation.

  Arterioscler Thromb Vasc Biol. 2016 Oct;36(10):2038-47. doi: 10.1161/ATVBAHA.116.306926. Epub 2016 Aug 25. Review.

• Tsuruya K, Fujisaki K.

  Cerebrovascular disease in end-stage kidney disease.

  Ren Rep Ther 2:29, 2016

• 升谷耕介

  腎移植 腎移植後の合併症 生活習慣病．

  腎と透析 80 (増) 腎と透析診療指針2016: 728-731, 2016

• 土本晃裕，升谷耕介，鶴屋和彦

  再発腎炎の診断・評価・留意点．

  今日の移植 29: 101-107, 2016

• 徳本正憲

  二次性副甲状腺機能亢進症の病態生理．

  Clinical Calcium 26 (6): 821-829, 2016

• 岡英明，原田篤実

  患者さんからの質問箱　クスリ　痛み止め(Q&A)．

  腎不全を生きる 53: 43, 2016

• 金井英俊

  糖尿病性腎症から透析へ　その問題点・最近の話題など　透析導入時期と問題点．

  jmed mook 42 (2): 152-157, 2016

• 永江洋，片渕律子

  腎機能低下の見つけ方．

  成人病と生活習慣病 46 (3): 321-326, 2016

• 片渕律子

  IgA腎症の重症度分類．

  腎と透析 80 (増) 腎と透析診療指針2016: 232-235, 2016

• 片渕律子

  免疫機能異常に由来する疾患 IgA腎症・紫斑病性腎炎．

  臨牀透析 32 (4): 407-414, 2016

• 藤﨑毅一郎，常喜信彦

  血液透析患者の心房細動とワルファリン投与．

  透析会誌: 49 (2): 176-177, 2016

• 升谷耕介

  腎移植患者の生活習慣病対策．

  腎と透析 80 (別) 腎不全外科2016: 38-41, 2016

• 升谷耕介

  ウイルス感染と腎移植．

  腎臓内科・泌尿器科 3 (2): 118-128, 2016

• 池田潔

  VA機能不全に対するPTA法の進歩と課題．

  日本透析医会雑誌 31 (1): 31-42, 2016

• 鶴屋和彦

  透析療法 長期透析の合併症治療 心臓・血管系合併症対策．

  腎疾患・透析最新の治療2017-2019．山縣邦弘，南学正臣 編，南江堂，東京，pp. ，2016

• 鶴屋和彦

  エリスロポエチン (EPO)．

  患者指導にすぐ使える透析患者の検査値ポケットブック，友雅司 編，メディカ出版，東京，pp.135-140，2016

• 鶴屋和彦

  腎性貧血．

  今日の治療指針 2016年版．山口徹，北原光夫 監修，医学書院，東京，pp.660-662，2016

• 鶴屋和彦

  脳血管障害．
  
  

  透析ケア 22 (8): 734-736, 2016

• 鶴屋和彦

  慢性腎臓病における脂質管理．

  臨牀と研究 93 (7): 949-955, 2016

• 鶴屋和彦

  CKDと脳血管疾患．

  日内会誌 105 (5): 825-833, 2016

• 鶴屋和彦

  CKDにおける貧血管理．

  腎と透析 80 (増) 腎と透析診療指針2016: 132-139, 2016

• 鶴屋和彦

  腎機能低下例での抗凝固療法．

  Cardio-Coagulation 3 (1): 22-30, 2016

• 鶴屋和彦

  糖尿病性腎症の治療はどうするの? 合併症を防ぐための治療はどうする? 脳血管障害．

  jmed mook 42 (2): 76-81, 2016

• 鶴屋和彦

  透析患者における脳血管障害の予防と管理．
  

  腎と透析 80 (1): 66-73, 2016

• 鶴屋和彦

  高齢CKD患者の管理．

  診断と治療のABC 111 (別冊): 187-196, 2016

その他

• 岡英明

  『維持血液透析患者における膿尿および尿細菌培養所見の検討』（中井靖，ほか）の論文について．

  透析会誌 49 (2): 196, 2016

• Eriguchi M, Tsuruya K.

  Renal sympathetic denervation in rats.

  Methods Mol Biol 1397: 45-52. 2016

• Horie S, Mochizuki T, Muto S, Hanaoka K, Fukushima Y, Narita I, Nutahara K, Tsuchiya K, Tsuruya K, Kamura K, Nishio S, Suwabe T, Ubara Y, Ishimura E, Nakanishi K, Furukawa K, Kimura K, Matsuo S.

  Evidence-based clinical practice guidelines for polycystic kidney disease 2014.

  Clin Exp Nephrol. 2016 Apr 20. [Epub ahead of print]

• Nishi S, Ubara Y, Utsunomiya Y, Okada K, Obata Y, Kai H, Kiyomoto H, Goto S, Konta T, Sasatomi Y, Sato Y, Nishino T, Tsuruya K, Furuichi K, Hoshino J, Watanabe Y, Kimura K, Matsuo S.

  Evidence-based clinical practice guidelines for nephrotic syndrome 2014.

  Clin Exp Nephrol. 2016 Apr 21. [Epub ahead of print]